Adherence to Antiparkinson medication in a Multicenter European study

Movement Disorders

Volumn 24, Issue 6, 2009, Pages 826-832

  Grosset, Donald ^a   Antonini, Angelo ^b   Canesi, Margherita ^b   Pezzoli, Gianni ^b   Lees, Andrew ^c   Shaw, Karen ^c   Cubo, Esther ^d   Martinez Martin, Pablo ^d   Rascol, Olivier ^e   Negre Pages, Laurence ^e   Senard, Ana ^e   Schwarz, Johannes ^f   Strecker, Karl ^f   Reichmann, Heinz ^g   Storch, Alexander ^g   Löhle, Matthias ^g   Stocchi, Fabrizio ^h   Grosset, Katherine ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b PARKINSON INSTITUTE   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Parkinson's disease; Therapy adherence

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; EUROPE; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PARKINSON DISEASE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 66249091092     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22112     Document Type: Article

References (20)

1. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310.
2. Urquhart J, de Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med 1998;17:251-267.
3. Giovannoni G, O'sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.
4. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2:595-604.
5. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord 2004;19:513-517.
6. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005;20:1502-1507.
7. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson's disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
9. Lee JY, Kusek JW, Greene PG, Bernhard S, Norris K, Smith D, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 1996;9:719-725.
10. Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J 1980;123:119-122.
11. Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA. Electronic monitoring and counseling to improve medication adherence. Behav Res Ther 2004;42:409-422.
12. Grosset KA, Bone I, Reid JL, Grosset D. Measuring therapy adherence in Parkinson's disease: a comparison of methods. J Neurol Neurosurg Psychiatry 2006;77:249-251.
13. Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A, Turner K, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007;78: 465-469.
14. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet 1994;27: 202-215.
15. Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 2003;18:487-495.
16. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002;17:1235-1241.
17. Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995;36:1111-1117.
18. Dhawan V, Dhoat S, Williams AJ, Dimarco A, Pal S, Forbes A, et al. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. J Neurol Sci 2006;248:158-162.
19. Serrano-Duenas M. Neuroleptic malignant syndrome-like, or - dopaminergic malignant syndrome - due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord 2003;9:175-178.
20. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord 2005;20:1397-1404.